ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
4.25B
Market cap4.25B
Price-Earnings ratio
11.67
Price-Earnings ratio11.67
Dividend yield
Dividend yield
Average volume
1.38M
Average volume1.38M
High today
$25.10
High today$25.10
Low today
$24.57
Low today$24.57
Open price
$25.10
Open price$25.10
Volume
1.02M
Volume1.02M
52 Week high
$28.35
52 Week high$28.35
52 Week low
$19.69
52 Week low$19.69

Stock Snapshot

The current ACADIA Pharmaceuticals(ACAD) stock price is $24.84, with a market capitalization of 4.25B. The stock trades at a price-to-earnings (P/E) ratio of 11.67.

On 2026-07-25, ACADIA Pharmaceuticals(ACAD) stock traded between a low of $24.57 and a high of $25.10. Shares are currently priced at $24.84, which is +1.1% above the low and -1.0% below the high.

ACADIA Pharmaceuticals(ACAD) shares are trading with a volume of 1.02M, against a daily average of 1.38M.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $28.35 and a 52-week low of $19.69.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $28.35 and a 52-week low of $19.69.

ACAD News

TipRanks 4d
Acadia Pharmaceuticals price target raised to $36 from $34 at BMO Capital

BMO Capital transferred its coverage on Acadia Pharmaceuticals (ACAD) to who raised the firm’s price target to $36 from $34 and keeps an Outperform rating on th...

Investing.com 4d
Stifel raises Acadia Pharmaceuticals price target on drug potential - Investing.com

...

Stifel raises Acadia Pharmaceuticals price target on drug potential - Investing.com
TipRanks 5d
Acadia Pharmaceuticals receives FDA Fast Track designation for remlifanserin

Acadia Pharmaceuticals (ACAD) announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to remlifanserin, an investigational...

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
19%
Sell
4.8%

More ACAD News

Simply Wall St 7d
ACADIA Pharmaceuticals Stock Trades At A Discount To Earnings But Faces Concentrated Risk

ACADIA Pharmaceuticals has returned about 19.3% over the past five years, yet recent valuation checks still flag the stock as screening cheap relative to its fu...

ACADIA Pharmaceuticals Stock Trades At A Discount To Earnings But Faces Concentrated Risk

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.